Genovis AB (publ.)

GENO · Nasdaq Stockholm · Healthcare

19.54SEK −0.7%last day

Price as of 2 October 2026

The price over the past year, with dividends: −16.0%

Performance

1 month

−9.1%

1 year

−16.0%

3 years, per year

−23.8%

5 years, per year

−18.8%

Largest fall, 3 years

−77.0%

Below the peak now

−80.5%

Volatility, 1 year

40.9%

Return with dividends reinvested.

Key figures

P/E

61.2

P/B

4.1

Dividend yield

0.0%

Return on equity

+6.7%

Net margin

+15.1%

Market value

129 m USD

Quality, value and trend

Where Genovis stands against every Nordic stock today. 100 is best.

Quality85

Profitability and a sound balance sheet over time. Better than 85% of Nordic stocks.

Value14

The price measured against earnings, assets and cash flow. Better than 14% of Nordic stocks.

Trend49

The price development over the past year. Better than 49% of Nordic stocks.

Combined45

Quality, value and trend together. Better than 45% of Nordic stocks.

About Genovis

Genovis AB (publ.) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 42 employees.

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis